Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Jeffrey Glassberg, MD
Healthcare Provider Associate Professor of Emergency Medicine
Mount Sinai School of Medicine
1190 Fifth Avenue
Third Floor
New York, New York, United States
Dr. Jeffrey Glassberg obtained his MD and a Masters’ degree in clinical research at Washington University in St. Louis School of Medicine in 2006. Dr. Glassberg completed his emergency medicine residency at NYU/Bellevue in 2010, followed by a research fellowship at Mount Sinai in July of 2012. Currently, Dr. Glassberg is funded by the National Heart Lung and Blood Institute by a K23 career development award and also holds an appointment at Rockefeller University as a visiting scientist.
Dr. Glassberg has become a leader in promoting evidence based strategies for the acute management of Sickle Cell Disease. He has several research focuses within Sickle Cell including pulmonary complications of Sickle Cell Disease, novel biomarkers for vaso-occlusive crises, and novel agents for the prevention and treatment of vaso-occlusion. In addition to practicing as an attending in the ED, Dr. Glassberg also sees patients in Sickle Cell clinic and serves as the primary physician for many patients with Sickle Cell disease who are at Mount Sinai. He is also active regionally and nationally as a member of the Queens Sickle Cell Advocacy Network, the New York Sickle Cell Advisory Council, and the Sickle Cell Disease Association of America.
Related Content
-
Lisa Pullens, RN, BSN, CPHNLisa received her RN-BSN 33 years ago at...
-
Deepa G. Manwani, MDDr. Manwani completed her residency (199...
-
NYC Health + HospitalsNYC Health + Hospitals are the largest p...
-
Four Solutions for Sickle Cell Disease SupportWhen Precious Lee was a year old, she be...
-
Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful CrisesOBJECTIVES: Sickle cell disease is the ...
-
GBT launches ACCEL grants program to improve access to care for people with Sickle cell diseaseGlobal Blood Therapeutics, Inc. (GBT) to...
-
Foundation For Sickle Cell Disease ResearchThe Foundation for Sickle Cell Disease R...